German Neuro Review close to first step on D3.
Posted: Sat Feb 09, 2013 2:27 am
I am pleased that these Neuros from Berlin are close to recommending D3 to a minimum blood level of 125mmol/L (they say 75-100mmol/L). I think they are not found all the published papers on this, maybe they should have read ThisIsMS. The paper is open access so you can read it at: http://www.epmajournal.com/content/4/1/4 . I printed the abstract below for those TiMS readers who do not want info overload.
I feel a letter to the author coming on.
MarkW
Can we prevent or treat multiple sclerosis by individualised vitamin D supply?
Jan Dörr1,2*, Andrea Döring1,2,3 and Friedemann Paul1,2
* Corresponding author: Jan Dörr jan-markus.doerr@charite.de
Author Affiliations
1 NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany
2 Clinical and Experimental Research Center for Multiple Sclerosis, Charité - Universitätsmedizin Berlin, Berlin, Germany
3 Current address: Department of Neurology, DIAKO, Flensburg, Germany
EPMA Journal 2013, 4:4 doi:10.1186/1878-5085-4-4
Abstract
Apart from its principal role in bone metabolism and calcium homeostasis, vitamin D has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamin D in autoimmune diseases like multiple sclerosis (MS). Indeed, several lines of evidence including epidemiologic, preclinical, and clinical data suggest that reduced vitamin D levels and/or dysregulation of vitamin D homeostasis is a risk factor for the development of multiple sclerosis on the one hand, and that vitamin D serum levels are inversely associated with disease activity and progression on the other hand. However, these data are not undisputable, and many questions regarding the preventive and therapeutic capacity of vitamin D in multiple sclerosis remain to be answered. In particular, available clinical data derived from interventional trials using vitamin D supplementation as a therapeutic approach in MS are inconclusive and partly contradictory. In this review, we summarise and critically evaluate the existing data on the possible link between vitamin D and multiple sclerosis in light of the crucial question whether optimization of vitamin D status may impact the risk and/or the course of multiple sclerosis.
Keywords:
Multiple sclerosis; Vitamin D; Cholecalciferol; Prevention; Therapy; Risk factor; Supplementation; Personalised medicine; Targeted prevention; Tailored therapy
I feel a letter to the author coming on.
MarkW
Can we prevent or treat multiple sclerosis by individualised vitamin D supply?
Jan Dörr1,2*, Andrea Döring1,2,3 and Friedemann Paul1,2
* Corresponding author: Jan Dörr jan-markus.doerr@charite.de
Author Affiliations
1 NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, Germany
2 Clinical and Experimental Research Center for Multiple Sclerosis, Charité - Universitätsmedizin Berlin, Berlin, Germany
3 Current address: Department of Neurology, DIAKO, Flensburg, Germany
EPMA Journal 2013, 4:4 doi:10.1186/1878-5085-4-4
Abstract
Apart from its principal role in bone metabolism and calcium homeostasis, vitamin D has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamin D in autoimmune diseases like multiple sclerosis (MS). Indeed, several lines of evidence including epidemiologic, preclinical, and clinical data suggest that reduced vitamin D levels and/or dysregulation of vitamin D homeostasis is a risk factor for the development of multiple sclerosis on the one hand, and that vitamin D serum levels are inversely associated with disease activity and progression on the other hand. However, these data are not undisputable, and many questions regarding the preventive and therapeutic capacity of vitamin D in multiple sclerosis remain to be answered. In particular, available clinical data derived from interventional trials using vitamin D supplementation as a therapeutic approach in MS are inconclusive and partly contradictory. In this review, we summarise and critically evaluate the existing data on the possible link between vitamin D and multiple sclerosis in light of the crucial question whether optimization of vitamin D status may impact the risk and/or the course of multiple sclerosis.
Keywords:
Multiple sclerosis; Vitamin D; Cholecalciferol; Prevention; Therapy; Risk factor; Supplementation; Personalised medicine; Targeted prevention; Tailored therapy